Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

Simple Summary This review aims to analyze the emerging issue regarding PARP inhibitor's
resistance in tumors and their consequence on disease prognosis and treatment. Besides …

Homologous recombination (HR) repair deficiency impairs the proper maintenance of
genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

BRCA1 and BRCA2 deficient tumor cells are sensitive to inhibitors of Poly ADP Ribose
Polymerase (PARP1) through the mechanism of synthetic lethality. Several PARP inhibitors …

Given the malleable nature of cancer cells, we should expect, and do see, the development
of resistance to any new chemotherapeutic agent. Models that help us understand how this …

The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …

Poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with deficiency for
homologous recombination (HR), a pathway essential for DNA double-strand break repair …

Simple Summary Targeted therapy has revolutionised oncological treatments in cancer with
great efficacy and a more tolerable side effect profile as compared to standard …

Abstract PARP (poly (ADP-ribose) polymerase) inhibitors represent a novel class of anti-
cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting …